Spherical nucleic acids as an infectious disease vaccine platform.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35312341.
- Also identified by DOI 10.1073/pnas.2119093119 and PMC identifier 9168922.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
SignificanceUsing SARS-CoV-2 as a relevant case study for infectious disease, we investigate the structure-function relationships that dictate antiviral spherical nucleic acid (SNA) vaccine efficacy. We show that the SNA architecture can be rapidly employed to target COVID-19 through incorporation of the receptor-binding domain, and that the resulting vaccine potently activates human cells in vitro and mice in vivo. Furthermore, when challenged with a lethal viral infection, only mice treated with the SNA vaccine survived. Taken together, this work underscores the importance of rational vaccine design for infectious disease to yield vaccines that elicit more potent immune responses to effectively fight disease.
Medical subject headings
- Communicable Disease Control
- Nucleic Acids
- Vaccines, DNA